

Aurelien Marabelle

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5179703/aurelien-marabelle-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

220
papers

13,589
citations

56
h-index

113
g-index

269
ext. papers

18,554
ext. citations

7.3
avg, IF

6.57
L-index

#	Paper	IF	Citations
220	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	2
219	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. <i>European Journal of Cancer</i> , 2022 , 163, 55-65	7.5	0
218	Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.. <i>European Journal of Cancer</i> , 2022 , 163, 98-107	7.5	
217	CD8PD-1 to CD4PD-1 ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. 2022 , 10,		2
216	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101874	2.2	27
215	Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox.. <i>European Journal of Cancer</i> , 2022 , 162, 128-129	7.5	0
214	The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in cancer patients and healthy individuals.. <i>Cancer Discovery</i> , 2022 ,	24.4	2
213	Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.. <i>European Journal of Cancer</i> , 2022 , 169, 188-197	7.5	0
212	Immune contexture of paediatric cancers. <i>European Journal of Cancer</i> , 2022 , 170, 179-193	7.5	0
211	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021 , 13, e12850	12	2
210	Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?. <i>Frontiers in Immunology</i> , 2021 , 12, 745146	8.4	0
209	Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V β V β T cell-mediated antitumor immune response. <i>Science Translational Medicine</i> , 2021 , 13, eabj0835	17.5	6
208	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. <i>European Journal of Cancer</i> , 2021 , 158, 217-224	7.5	3
207	Tumour burden and efficacy of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	17
206	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021 , 12, 258	9.8	37
205	Vaincre les résistances aux antagonistes de checkpoint en augmentant l'immunogénéité de la tumeur. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2021 , 205, 340-349	0.1	
204	CAR-T cells and BiTEs in solid tumors: challenges and perspectives. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 65	22.4	11

203	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021 , 11, 874-899	24.4	26
202	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2565-2565	2.2	2
201	Applications of single-cell and bulk RNA sequencing in onco-immunology. <i>European Journal of Cancer</i> , 2021 , 149, 193-210	7.5	11
200	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 558-576	19.4	48
199	SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC). <i>European Journal of Cancer</i> , 2021 , 148, 121-123	7.5	8
198	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021 , 28, 3297-3315	12.7	7
197	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 36-48	2.4	61
196	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 221-232	7.4	7
195	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 492-503	12.9	31
194	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. <i>Clinical Cancer Research</i> , 2021 , 27, 665-679	12.9	19
193	Interventional Radiology for Local Immunotherapy in Oncology. <i>Clinical Cancer Research</i> , 2021 , 27, 2698-2705	12.9	9
192	An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 429-429	2.2	
191	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 2755-2763	12.9	5
190	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.. <i>Nature Cancer</i> , 2021 , 2, 794-802	15.4	19
189	Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021 , 157, 493-510	7.5	4
188	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. <i>European Journal of Cancer</i> , 2021 , 156, 46-59	7.5	2
187	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021 , 3, fcab220	4.5	2
186	Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks. <i>European Journal of Cancer</i> , 2021 , 156, 217-221	7.5	

185	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021 , 157, 383-390	7.5	2
184	Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2667-2676	2.2	18
183	First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE-receptor E-type 4 (EP4), in patients with advanced cancers 2020 , 8,		16
182	A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. <i>ERJ Open Research</i> , 2020 , 6,	3.5	1
181	Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. <i>European Journal of Cancer</i> , 2020 , 129, 71-79	7.5	21
180	Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2301-2312	8.8	31
179	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020 , 130, 39-50	7.5	17
178	Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies 2020 , 8,		9
177	Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 707-715	19.4	28
176	Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion. <i>European Journal of Cancer</i> , 2020 , 135, 192-202	7.5	3
175	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). <i>Clinical Cancer Research</i> , 2020 , 26, 2461-2465	12.9	2
174	Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. <i>Oncologist</i> , 2020 , 25, 369-374	5.7	7
173	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020 , 9, 2643-2652	4.8	14
172	Hyperprogression upon immunotherapy: A chance for (hyper-)progress. <i>European Journal of Cancer</i> , 2020 , 126, 139-140	7.5	2
171	Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. <i>Annals of Oncology</i> , 2020 , 31, 961-964	10.3	222
170	Repurposing infectious disease vaccines for intratumoral immunotherapy 2020 , 8,		13
169	291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors 2020 , 8, A318-A318		2
168	316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A 2020 , 8, A342-A342		2

167	794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors 2020 , 8, A842-A842		
166	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1-10	2.2	786
165	Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. <i>JACC: CardioOncology</i> , 2020 , 2, 599-610	3.8	18
164	Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors 2020 , 8,		9
163	The immuno-oncological challenge of COVID-19.. <i>Nature Cancer</i> , 2020 , 1, 946-964	15.4	52
162	Tumour mutational burden in treatment-resistant tumours - Authors' reply. <i>Lancet Oncology, The</i> , 2020 , 21, e552	21.7	2
161	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. <i>European Journal of Cancer</i> , 2020 , 141, 239-251	7.5	10
160	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 137, 117-126	7.5	8
159	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020 , 182, 1401-1418.e18	56.2	359
158	Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. <i>Cancer Discovery</i> , 2020 , 10, 1097-1099	24.4	2
157	Chemokine biology on immune checkpoint-targeted therapies. <i>European Journal of Cancer</i> , 2020 , 137, 260-271	7.5	8
156	Immune responses during COVID-19 infection. <i>OncImmunity</i> , 2020 , 9, 1807836	7.2	49
155	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology, The</i> , 2020 , 21, 1353-1365	21.7	500
154	Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 49-64	19.4	41
153	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020 , 580, 517-523	50.4	172
152	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019 , 29, 846-861	24.7	91
151	Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. <i>European Journal of Cancer</i> , 2019 , 119, 44-56	7.5	13
150	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1310-1317	13.4	161

149	Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection. <i>Clinical Cancer Research</i> , 2019 , 25, 6283-6294	12.9	24
148	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 81-88	4.5	61
147	T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. <i>Annals of Oncology</i> , 2019 , 30, 934-944	10.3	8
146	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 3220-3228	12.9	99
145	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. <i>American Journal of Ophthalmology</i> , 2019 , 202, 109-117	4.9	42
144	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e67	2.4	31
143	Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?. <i>Annals of Oncology</i> , 2019 , 30, 1751-1759	10.3	10
142	Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2298-2310	8.8	55
141	Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	34
140	PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 1211-1228	15.9	139
139	Targeting CD137 enhances the efficacy of cetuximab. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2595	15.9	4
138	A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours. <i>Blood</i> , 2019 , 134, 1040-1040	2.2	2
137	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study 2019 , 7, 337		45
136	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. <i>European Journal of Cancer</i> , 2019 , 108, 111-119	7.5	7
135	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?". <i>Journal of Hepatology</i> , 2019 , 70, 566-567	13.4	1
134	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology,the</i> , 2019 , 6, e48-e57	14.6	109
133	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Letter. <i>Clinical Cancer Research</i> , 2019 , 25, 3468	12.9	13
132	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019 , 25, 946-956	12.9	67

131	Remitting Seronegative Symmetric Synovitis With Pitting Edema Associated With Partial Melanoma Response Under Anti-CTLA-4 and Anti-Programmed Death 1 Combination Treatment. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1358	9.5	7
130	Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. <i>European Journal of Cancer</i> , 2018 , 95, 68-74	7.5	13
129	Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2018 , 91, 136-144	7.5	26
128	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018 , 92, 1-10	7.5	11
127	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018 , 68, 1181-1190	13.4	222
126	Tumor-Targeted Antibodies 2018 , 311-319		
125	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , 2018 , 91, 21-29	7.5	158
124	Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2018 , 29, 518-520	10.3	9
123	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. <i>European Journal of Cancer</i> , 2018 , 96, 91-104	7.5	73
122	F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 15-24	8.9	78
121	Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. <i>European Journal of Cancer</i> , 2018 , 101, 160-164	7.5	39
120	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". <i>Journal of Hepatology</i> , 2018 , 69, 550-551	13.4	0
119	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. <i>Lancet Oncology, The</i> , 2018 , 19, 1180-1191	21.7	456
118	Reply to: "Mortality due to immunotherapy related hepatitis". <i>Journal of Hepatology</i> , 2018 , 69, 978-979	13.4	
117	Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3080-3080	2.2	4
116	A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3094-3094	2.2	5
115	Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5522-5522	2.2	44
114	Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 49-49	2.2	3

113	Association of stromal lymphocyte infiltration with tumor invasion depth and high-grade T1 bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 488-488	2.2	1
112	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018 , 9, 9741-9750	3.3	7
111	Anticorps monoclonaux en oncologie : déclencher une réponse immunitaire en plus de la réduction tumorale spécifique.. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2018 , 202, 707-735	0.1	
110	Medical image computing to assess tumor infiltrating CD8 T cells, tumor immune phenotype and response to anti-PD-1/PD-L1 immunotherapy in prospective phase 1 trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3016-3016	2.2	
109	Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies. <i>Blood</i> , 2018 , 132, 2412-2412	2.2	
108	Introduction to Pediatric Cancer Immunotherapy 2018 , 1-11		
107	Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis. <i>JAMA Dermatology</i> , 2018 , 154, 113	5.1	4
106	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018 , 88, 38-47	7.5	178
105	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". <i>Journal of Hepatology</i> , 2018 , 69, 1397-1398	13.4	1
104	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors 2018 , 6, 93		37
103	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). <i>Annals of Oncology</i> , 2018 , 29, 2163-2174	10.3	88
102	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 748-762	19.4	206
101	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>Annals of Oncology</i> , 2018 , 29, 2175-2182	10.3	13
100	Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. <i>European Journal of Cancer</i> , 2018 , 98, 17-22	7.5	5
99	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. <i>OncImmunology</i> , 2017 , 6, e1137418	7.2	37
98	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. <i>OncImmunology</i> , 2017 , 6, e1163456	7.2	22
97	JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. <i>Cancer Discovery</i> , 2017 , 7, 128-130	24.4	15
96	Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. <i>European Journal of Cancer</i> , 2017 , 75, 308-309	7.5	5

95	Pattern recognition receptors: immune targets to enhance cancer immunotherapy. <i>Annals of Oncology</i> , 2017 , 28, 1756-1766	10.3	78
94	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 2433-2441 ¹²⁻⁹	12.9	92
93	Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1747-1750	2.4	148
92	Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN- γ Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. <i>Cancer Research</i> , 2017 , 77, 4146-4157	10.1	79
91	Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma. <i>Cancer Cell</i> , 2017 , 32, 427-443.e8	24.3	36
90	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. <i>Annals of Oncology</i> , 2017 , 28, 2860-2865	10.3	71
89	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017 , 84, 212-218	7.5	78
88	Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). <i>European Journal of Cancer</i> , 2017 , 84, 202-211	7.5	25
87	Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. <i>European Journal of Cancer</i> , 2017 , 84, 290-303	7.5	89
86	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017 , 85, 155-157	7.5	5
85	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017 , 8, 592	17.4	122
84	Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2017 , 85, 67-77	7.5	16
83	Safety of treatment with nivolumab after ipilimumab-related meningo-radiculitis and bilateral optic neuropathy. <i>European Journal of Cancer</i> , 2017 , 83, 28-31	7.5	27
82	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. <i>European Journal of Cancer</i> , 2017 , 82, 34-44	7.5	110
81	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2017 , 23, 1920-1928	12.9	698
80	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 194-207	8.9	132
79	Intratumoral immunotherapy: using the tumor as the remedy. <i>Annals of Oncology</i> , 2017 , 28, xii33-xii43	10.3	134
78	Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors 2017 ,		8

77	Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2549-2549	2.2	1
76	Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3002-3002	2.2	85
75	Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3071-3071	2.2	76
74	LTX-315, an oncolytic peptide, to convert immunogenically 'cold' tumors to 'hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3085-3085	2.2	2
73	Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5514-5514	2.2	49
72	Overall survival prognosis of patients in immuno-oncology phase I trials: The Gustave Roussy score.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3029-3029	2.2	
71	A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14627-e14627	2.2	
70	Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?. <i>European Journal of Cancer</i> , 2016 , 68, 134-147	7.5	69
69	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1819-1836	8.9	22
68	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials 2016 , 4, 15		47
67	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016 , 54, 139-148	7.5	1239
66	Prime time for immune-checkpoint targeted therapy at ASCO 2015. <i>OncImmunology</i> , 2016 , 5, e1068494	7.2	5
65	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 994-1001	4.3	20
64	Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?. <i>OncImmunology</i> , 2016 , 5, e1112942	7.2	16
63	Two cases of immune thrombocytopenia associated with pembrolizumab. <i>European Journal of Cancer</i> , 2016 , 54, 172-174	7.5	47
62	Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues. <i>European Journal of Cancer</i> , 2016 , 58, 8-16	7.5	18
61	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. <i>Annals of Oncology</i> , 2016 , 27, 559-74	10.3	548
60	Rationale for anti-OX40 cancer immunotherapy. <i>European Journal of Cancer</i> , 2016 , 52, 50-66	7.5	193

59	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , 2016 , 27, 214-24	10.3	67
58	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016 , 126, 921-37	15.9	48
57	Phase 1 study of E7046, an inhibitor of the PGE2 receptor EP-4, that targets immunosuppressive myeloid cells in the tumor microenvironment (NCT02540291).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e141116-e141116	2.2	1
56	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2016 , 22, 4309-21	12.9	127
55	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Oncolimmunology</i> , 2016 , 5, e1186323	7.2	2
54	Holbrook Kohrt: In Memoriam (1977-2016). <i>Clinical Cancer Research</i> , 2016 , 22, 3695-6	12.9	
53	Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis. <i>Oncolimmunology</i> , 2016 , 5, e1120399	7.2	8
52	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. <i>European Journal of Cancer</i> , 2016 , 62, 36-45	7.5	81
51	A tribute to the life and career of Holbrook Kohrt. <i>Annals of Oncology</i> , 2016 , 27, 1183-4	10.3	
50	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. <i>Annals of Oncology</i> , 2016 , 27, 1482-92	10.3	335
49	The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. <i>Cell Death and Differentiation</i> , 2016 , 23, 1004-15	12.7	46
48	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 473-86	19.4	591
47	Biomarkers associated with checkpoint inhibitors. <i>Annals of Oncology</i> , 2016 , 27, 1199-206	10.3	112
46	The oncolytic compound LTX-401 targets the Golgi apparatus. <i>Cell Death and Differentiation</i> , 2016 , 23, 2031-2041	12.7	16
45	Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. <i>European Journal of Cancer</i> , 2016 , 66, 91-4	7.5	42
44	Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. <i>European Journal of Cancer</i> , 2016 , 65, 33-42	7.5	39
43	Paradigm shift in oncology: targeting the immune system rather than cancer cells. <i>Mutagenesis</i> , 2015 , 30, 205-11	2.8	36
42	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolimmunology</i> , 2015 , 4, e1008814	7.2	68

41	Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94. <i>Strahlentherapie Und Onkologie</i> , 2015 , 191, 604-12	4.3	25
40	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. <i>Science Translational Medicine</i> , 2015 , 7, 283ra55	17.5	97
39	T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2015 , 3, 1115-22	12.5	121
38	Checkpoint immunologique comme cible thérapeutique. <i>Oncologie</i> , 2015 , 17, 354-371	1	
37	Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. <i>Cancer Research</i> , 2015 , 75, 4517-26	10.1	49
36	Radiotherapy and toll-like receptor agonists. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 34-9	5.5	20
35	How should we use anti-CTLA-4 antibodies?. <i>European Journal of Cancer</i> , 2015 , 51, 2686-8	7.5	5
34	Detection of tumor ALK status in neuroblastoma patients using peripheral blood. <i>Cancer Medicine</i> , 2015 , 4, 540-50	4.8	55
33	Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1317-25	3	11
32	In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer. <i>Journal of Immunology Research</i> , 2015 , 2015, 482089	4.5	15
31	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>OncolImmunology</i> , 2015 , 4, e985940	7.2	38
30	Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. <i>Current Opinion in Immunology</i> , 2015 , 33, 1-8	7.8	22
29	TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. <i>Cancer Letters</i> , 2015 , 357, 412-418	9.9	34
28	Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. <i>Chinese Clinical Oncology</i> , 2015 , 4, 48	2.3	5
27	Effect of CD137 stimulation on ibrutinib antagonism of GA101 dependent NK cell-mediated cytotoxicity.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3075-3075	2.2	
26	Intratumoral immunization: a new paradigm for cancer therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 1747-56.9	5.9	153
25	Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. <i>Blood</i> , 2014 , 123, 678-86	2.2	207
24	Targeting CD137 enhances the efficacy of cetuximab. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2668-82.5.9	5.9	137

23	Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN. <i>PLoS ONE</i> , 2014 , 9, e101990	3.7	12
22	New insights into the mechanism of action of immune checkpoint antibodies. <i>Oncology</i> , 2014 , 3, e954869	7.2	9
21	The Tetraspanin CD81 Facilitates Tumor Metastasis By Modulating Immune Suppression. <i>Blood</i> , 2014 , 124, 4136-4136	2.2	
20	Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. <i>Clinical Cancer Research</i> , 2013 , 19, 5261-3	12.9	44
19	Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2447-63	15.9	285
18	Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4980-4980	15.9	2
17	Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies. <i>Blood</i> , 2013 , 122, 4417-4417	2.2	1
16	Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine. <i>Blood</i> , 2012 , 120, 4454-5	2.2	6
15	Combination strategies to enhance antitumor ADCC. <i>Immunotherapy</i> , 2012 , 4, 511-27	3.8	71
14	NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT. <i>Pediatric Blood and Cancer</i> , 2012 , 59, 739-42	3	24
13	Clear cell ependymoma with trisomy 19 developing bone metastases. <i>Childs Nervous System</i> , 2012 , 28, 739-42	1.7	6
12	Targeting B-Cell Lymphoma with Idiotypic-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy. <i>Blood</i> , 2012 , 120, 3713-3713	2.2	
11	Active and passive immunotherapy for lymphoma: proving principles and improving results. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1864-75	2.2	33
10	Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. <i>Trends in Immunology</i> , 2011 , 32, 510-6	14.4	50
9	Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. <i>Pediatric Blood and Cancer</i> , 2011 , 56, 757-61	3	24
8	CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2011 , 56, 134-42	3	13
7	Hemophagocytic syndrome revealing primary HHV-6 infection. <i>Journal of Pediatrics</i> , 2010 , 157, 511	3.6	8
6	Cabergoline therapy of paraneoplastic Cushing syndrome in children. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 589-90	3	2

5	Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2009 , 52, 280-3	3	11
4	Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model. <i>Bone Marrow Transplantation</i> , 2008 , 42 Suppl 2, S25-30	4.4	22
3	Focal nodular hyperplasia of the liver in patients previously treated for pediatric neoplastic diseases. <i>Journal of Pediatric Hematology/Oncology</i> , 2008 , 30, 546-9	1.2	17
2	Graft-versus-tumour effect in refractory metastatic neuroblastoma. <i>Bone Marrow Transplantation</i> , 2007 , 39, 809-10	4.4	21
1	Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. <i>Transfusion</i> , 2007 , 47, 2276-89	2.9	74